drugset / Trial / NCT01030640

Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

NCT01030640

Phase 1 Completed 28 enrolled Pfizer
Non-randomizedParallel-groupDouble-blindTreatment

Summary

Subcutaneous administration of tanezumab can result in changes in the number of nerves around the injection site in the thigh.

Timeline

Start
2009-12
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tanezumab Monoclonal antibody 20 mg Subcutaneous